Similar articles

• The author replies.

  Jensen JU. Jensen JU. Crit Care Med. 2015 Aug;43(8):e323. doi: 10.1097/CCM.0000000000001108. Crit Care Med. 2015. PMID: 26181129 No abstract available.
• Fluoroquinolones: another line in the long list of their collateral damage record.

  Paiva JA, Pereira JM. Paiva JA, et al. Crit Care Med. 2015 Mar;43(3):708-10. doi: 10.1097/CCM.0000000000000802. Crit Care Med. 2015. PMID: 25700059 No abstract available.
• Invasive Candida infections and the harm from antibacterial drugs in critically ill patients: data from a randomized, controlled trial to determine the role of ciprofloxacin, piperacillin-tazobactam, meropenem, and cefuroxime.

  Jensen JU, Hein L, Lundgren B, Bestle MH, Mohr T, Andersen MH, Løken J, Tousi H, Søe-Jensen P, Lauritsen AØ, Strange D, Petersen JA, Thormar K, Larsen KM, Drenck NE, Helweg-Larsen J, Johansen ME, Reinholdt K, Møller JK, Olesen B, Arendrup MC, Østergaard C, Cozzi-Lepri A, Grarup J, Lundgren JD; Procalcitonin and Survival Study Group. Jensen JU, et al. Crit Care Med. 2015 Mar;43(3):594-602. doi: 10.1097/CCM.0000000000000746. Crit Care Med. 2015. PMID: 25493970 Clinical Trial.
• Role of probiotics in prevention of Candida infection in critically ill children.

  Kumar S, Singhi S. Kumar S, et al. Mycoses. 2013 May;56(3):204-11. doi: 10.1111/myc.12021. Epub 2012 Nov 26. Mycoses. 2013. PMID: 23176162 Review.
• Risk Factors for Invasive Candida Infection in Critically Ill Patients: A Systematic Review and Meta-analysis.

  Thomas-Rüddel DO, Schlattmann P, Pletz M, Kurzai O, Bloos F. Thomas-Rüddel DO, et al. Chest. 2022 Feb;161(2):345-355. doi: 10.1016/j.chest.2021.08.081. Epub 2021 Oct 18. Chest. 2022. PMID: 34673022 Free PMC article.